Tests ways to help families get screened for familial hypercholesterolemia
Compares outreach methods to encourage relatives of people with familial hypercholesterolemia to get screened.
Key facts
- Who runs it
- Northwestern University
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Penn Family Screening for Familial Hypercholesterolemia
- Status
- Enrolling by invitation
- People taking part
- 800 people, planned
- Started
- 24 Jan 2023
- Expected to end
- 28 Feb 2027
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Cascade screening
- Record updated
- 9 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a clinical diagnosis of familial hypercholesterolemia who are treated at Penn Medicine and can share screening information with a close relative.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Clinically diagnosed familial hypercholesterolemia (FH)
- Earlier treatment
- Treated within the Penn Medicine system
Main reasons for not taking part
- Under age 18
- No contact information for at least one living first-degree biological relative
- No cell phone with texting and no access to email
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adults aged 18 years and older with clinically diagnosed FH who are treated within the Penn Medicine system
- Have contact information for at least one living, first-degree biological relative
- Have a cell phone with texting capabilities and/or access to email
Who cannot take part
- People under age 18
- Do not have contact information for at least one living, first-degree biological relative
- Do not have a cell phone with texting capabilities nor access to email
Where in United States
- University of Pennsylvania Perelman School of MedicinePhiladelphia, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The goal of this clinical trial is to test two implementation strategies (automated health system [Penn Medicine]-mediated strategy vs. Family Heart Foundation-mediated strategy using a patient navigator) versus usual care to promote family cascade screening for familial hypercholesterolemia (FH) in Penn Medicine patients diagnosed with FH ("probands"). The main questions this study aims to answer are: (1) evaluating the effect of the three approaches on reach (proportion of probands who have at least one family member who completes screening), number of family members screened, number of family members diagnosed with FH, and proband LDL-C levels; and (2) identifying implementation strategy mechanisms focusing on health equity using mixed methods and oversampling populations that experience disparities. Participants (probands) in the active arms (health system [Penn Medicine]-mediated, Family Heart Foundation-mediated) will receive messaging that provides education about FH and provides instructions for participating in family cascade screening. A subset of probands will be invited to complete a qualitative interview about their experience receiving the implementation strategy. The research team will compare the active arms to Penn Medicine usual care for cascade screening to evaluate whether the active arms are more effective at promoting cascade screening than usual care.
The 3 groups in the trial
- Penn Medicine (health system)-mediatedTreatment being tested
Probands receive automated text messages and/or emails through the Way to Health (WTH) platform containing information about FH and cascade screening from Penn Medicine, and a request to identify first-degree biological relatives. Probands choose whether to contact relatives themselves or share contact information so that automated text messages and/or emails can be sent by Penn Medicine to relatives directly via WTH. If probands opt to contact relatives themselves (self-contact), they receive tips on how to do this effectively. If probands opt for Penn Medicine to contact their relatives (direct contact), relatives receive information via WTH about FH and instructions for screening. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
Treatment: Cascade screening
- Family Heart Foundation-mediatedTreatment being tested
After using WTH to conduct an identity screen and giving probands an option to opt-out of having their information shared with Family Heart Foundation (FHF), FHF reaches out directly to probands via an FHF-employed navigator. During an initial call, the navigator introduces the proband to navigation services, conducts a social history, and initiates a plan for contacting relatives. Probands choose whether to contact relatives themselves (self-contact) or have FHF contact relatives directly (direct contact). Those who choose self-contact receive personalized coaching to address barriers and concerns. For direct contact relatives, FHF will call these relatives directly. All relatives (regardless of whether they were contacted via self-contact and direct contact) will be offered FH screening at no cost. If a proband's initial choice of outreach is not successful, they will have the option of initiating the alternate outreach approach (direct or self-contact).
Treatment: Cascade screening
- Usual CareNo study treatment, for comparison
Probands randomized to this arm will not receive any contact from the research team or Family Heart Foundation regarding cascade screening (i.e., no intervention).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Leveraging Behavioral Economics to Equitably Implement Cascade Screening in Individuals With Familial Hypercholesterolemia in Partnership With the FH Foundation (R33 Phase)
- Plain-language title
- Tests ways to help families get screened for familial hypercholesterolemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 9 February 2026